System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Jérôme Boursier is an expert in Hepatology at Centre Hospitalier Universitaire d'Angers (France). As of October 2026, ScienceLeadR ranks Jérôme Boursier in the top 1% of experts worldwide for MASH, Fatty Liver, Alcoholic and Liver Diseases, Alcoholic. Jérôme Boursier has authored 440 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 12 of them ongoing. SLR score: 2,231 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Jérôme Boursier Centre Hospitalier Universitaire d'Angers France
2 231 ScienceLeadR Reputation 2231

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Université Nantes Angers Le Mans

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 440

Citations

Citations: 26 136 1st author: 72 Last author: 38 Unique author: 3

Main journals

J Hepatol 130
Hepatology 28
Clin Gastroenterol Hepatol 23
Liver Int 20
Clin Res Hepatol Gastroenterol 13

Best Journals

J Hepatol 34
N Engl J Med 5
Lancet Gastroenterol Hepatol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.
PMID 42613687 — liver diseases, hypertension, carcinoma, hepatocellular, cholangitis, fibrosis, non-alcoholic fatty liver disease, liver, hypertension, portal, therapeutics, hepatitis, peroxisome proliferator-activated receptors		Liver Int20260
Implications of new obesity definitions in the classification and outcomes of patients with MASLD.
PMID 42507833 — liver diseases, diabetes mellitus, incidence, classification, liver, obesity, overweight		Hepatology20261
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.
PMID 42498741 — serum, fibrosis, elasticity imaging techniques, non-alcoholic fatty liver disease, liver, biomarkers		Nat Med Top journal20268
Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).
PMID 42476208 — liver diseases, fibrosis, biopsy, liver, machine learning, learning		Clin Gastroenterol Hepatol20260
Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0.
PMID 42467969 — liver diseases, gastroenterology, fibrosis, pathologists, biopsy, liver, diagnosis		Am J Gastroenterol20260

Clinical Studies 37

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Chair: 1

By phase:

N/A 18
Phase 3 12
Phase 2 7

By status:

Completed 16
Recruiting 10
Active not recruiting 5
Terminated 3
Not yet recruiting 2
Unknown 1

By type:

Interventional 30
Observational 7

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 2
multicentric5to9 5
multicentricup10 24

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH)
2024-512895-36-00 — safety, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol related liver disease
2024-511596-15-00 — liver diseases, safety, liver, aged		Phase 2Recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
The MAI FOIE Cohort
NCT07594990 — liver diseases, liver, biomarkers		N/ANot yet recruiting2026
Impact of Artificial Intelligence Algorithm driven Versus Standard Lifestyle Intervention in Non Alcoholic Fatty Liver Disease A Multicenter Randomized Open label Controlled Trial
NCT07497750 — liver diseases, diabetes mellitus, depression, exercise, quality of life, intelligence, life style, eating, fibrosis, pain, non-alcoholic fatty liver disease, cooking, health status, magnetic resonance imaging, liver, algorithms, biomarkers, diet, alcoholics, food, work, software, meals, artificial intelligence, history, tissues, sedentary behavior, fatty liver, random allocation, snacks, patient satisfaction, fatty liver, alcoholic, lifestyle and wellness apps, fibroscan, lipids, liver stiffness		N/ANot yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS